Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., Geron’s president and chief executive officer, will present an update of the company’s product development programs at 11 a.m. ET on Monday, Feb. 11, 2008, at the BIO CEO & Investor Conference in New York City.

The update of Geron’s portfolio of telomerase-based anti-cancer therapies will include the inhibitor drug, GRN163L, and the therapeutic vaccine, GRNVAC1. New information about the company’s second generation human embryonic stem cell-based cancer vaccine, GRNVAC2, will also be presented. Additionally, the presentation will include reviews of the company’s human embryonic stem cell development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1) and diabetes (GRNIC1).

An audio Webcast of the presentation will be available at the following Web site address: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=GERN&item_id= 1753453. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

A replay will be available at this address within 24 hours of the presentation and for a period of 30 days.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.

Contacts:

Russo Partners, LLC
Media and Investors:
David Schull, 858-717-2310
david.schull@russopartnersllc.com
or
Russo Partners, LLC
Tracey Milani, 619-814-3511
tracey.milani@russopartnersllc.com
or
Geron
David L. Greenwood, 650-473-7765
Chief Financial Officer
info@geron.com